Clinical Trial

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL

Study acronym: XP-006
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. Secondary objectives focus on evaluating preliminary efficacy through several parameters: XP-006-induced antigen-specific CD4+/CD8+ T cell activation levels, objective remission rate (ORR), complete remission rate (CRR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-03.
Trial Details
NCT Number NCT07334574
Lead Sponsor Ruijin Hospital
Collaborators: Shanghai Xinpu BioTechnology Company Limited
Conditions B-cell Non-Hodgkin's Lymphoma (B-NHL)
Enrollment 20 participants
Start Date 2026-01-15
Primary Completion 2028-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-13